Table 2. Comparison of Modified Rai... | American Society of Hematology

Table 2.

Comparison of Modified Rai Stage at Diagnosis With Ig V Gene Mutation Status and the Percentages of CD38⁺ B-CLL Cells

Stage	Unmutated	Mutated
Low^*	22.7% (5/22)	52.4% (11/21)
Intermediate^*	72.7% (16/22)	42.9% (9/21)
High	4.6% (1/22)	4.7% (1/21)
	P = .123
	≥30% CD38⁺ B-CLL Cells	<30% CD38⁺ B-CLL Cells
Low^†	20.0% (3/15)	50.0% (9/18)
Intermediate^†	73.3% (11/15)	50.0% (9/18)
High	6.7% (1/15)	0.0% (0/18)
	P = .138

Stage	Unmutated	Mutated
Low^*	22.7% (5/22)	52.4% (11/21)
Intermediate^*	72.7% (16/22)	42.9% (9/21)
High	4.6% (1/22)	4.7% (1/21)
	P = .123
	≥30% CD38⁺ B-CLL Cells	<30% CD38⁺ B-CLL Cells
Low^†	20.0% (3/15)	50.0% (9/18)
Intermediate^†	73.3% (11/15)	50.0% (9/18)
High	6.7% (1/15)	0.0% (0/18)
	P = .138

Comparison of V gene mutation status among patients in the low and intermediate risk categories (P = .058; 2-tailed Fisher’s Exact test).

Comparison of CD38 expression among patients in the low and intermediate risk categories (P = .147; 2-tailed Fisher’s Exact test).